latest update:
[TrialBase DB]

trial summary · NCT07871071

Brain-Computer Interface Communication Device for People With ALS

Within-Subject Longitudinal Evaluation of the Cognixion ONE Brain-Computer Interface Speech Generating Device in Individuals With ALS

Trial record from the TrialBase DB dataset, status RECRUITING, condition Amyotrophic Lateral Sclerosis, sponsored by Cognixion. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07871071phase —enrollment 30start 2026-11-15

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This study compares a wearable brain-computer interface (BCI) communication device with the eye-tracking communication devices that people with ALS already use. As ALS progresses, speech is lost and many people come to rely on an eye-tracking speech generating device. Eye-tracking performance can decline as oculomotor control is affected, and some people reach a point where it no longer works reliably for them. The Cognixion ONE device adds a brain-computer interface input, which does not depend on eye movement, alongside an AI-assisted communication application. Thirty adults with ALS who currently use a Tobii Dynavox or Smartbox eye-tracking device will take part. Each participant uses three communication options at home over a 12-week period: their own eye-tracking device, the Cognixion ONE device with a head-worn augmented-reality display, and the Cognixion ONE device with a screen-based display. For some sessions the option is assigned; for others the participant chooses. The main measure is how much time participants voluntarily choose to spend using each option. That choice is treated as the clearest signal of which option genuinely works better for them. The study also measures communication speed and accuracy, usability, workload, quality of life, and caregiver burden. The Cognixion ONE device is an investigational research device. It is not approved or cleared by the U.S. Food and Drug Administration for any medical use.

Source record: https://clinicaltrials.gov/study/NCT07871071

Facts

registry idNCT07871071
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasenot reported
study typeINTERVENTIONAL
lead conditionAmyotrophic Lateral Sclerosis
sponsorCognixion
sponsor classINDUSTRY
enrollment30
start date2026-11-15
primary completion2028-04
completion2029-06
results postednot reported

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • Cognixion ONE AR-BCI configuration
  • Cognixion ONE screen-based BCI configuration
  • Existing eye-gaze speech generating device

Countries

  • United States

Intervention types: DEVICE

Work with this record